Skip to main content
Top

Open Access 02-06-2025 | Vasculitis | CASE BASED REVIEW

Treatment and long-term follow-up of pediatric patients with hypocomplementemic urticarial vasculitis syndrome (HUVS): a case-based review

Authors: Özen Taş, Fatma Aydın, Zeynep Birsin Özçakar

Published in: Clinical Rheumatology

Login to get access

Abstract

Hypocomplementemic urticarial vasculitis syndrome (HUVS) is a rare, severe form of urticarial vasculitis. It is characterized by persistent hypocomplementemia, chronic urticarial vasculitic lesions, and severe multiorgan involvement. Herein, we present long-term follow-up of two siblings diagnosed with HUVS at early ages, who were found to have DNASE1L3 mutations, and their subsequent 20-year follow-up. While one of the siblings developed lupus nephritis, the other exhibited vasculitic renal involvement. The patients received various treatments, with rituximab proving most effective in the long term. The present study contributes to the existing body of literature on pediatric HUVS, which, to the best of our knowledge, has been described in 28 cases. Renal involvement was present in 82% of patients, and lupus nephritis was most common in patients with renal pathology. Patients received many different treatments. Two patients died, and five patients developed end-stage renal failure. However, it should be noted that follow-up was not conducted in 39% of these patients and the follow-up period was very short for the remaining patients.
Literature
This content is only visible if you are logged in and have the appropriate permissions.
Metadata
Title
Treatment and long-term follow-up of pediatric patients with hypocomplementemic urticarial vasculitis syndrome (HUVS): a case-based review
Authors
Özen Taş
Fatma Aydın
Zeynep Birsin Özçakar
Publication date
02-06-2025
Publisher
Springer International Publishing
Published in
Clinical Rheumatology
Print ISSN: 0770-3198
Electronic ISSN: 1434-9949
DOI
https://doi.org/10.1007/s10067-025-07509-6

Innovations in AML: insights and practical guidance

Hear directly from acute myeloid leukemia experts in this vodcast series focussing on innovations in molecular testing, emerging therapies, and targeted treatments, and get practical advice for improving the care of your patients with relapsed or refractory disease.

Supported by:
  • Rigel Pharmaceuticals, Inc.
Developed by: Springer Health+ IME
Learn more

ADA 2025

Unlock your free and exclusive access to the latest news from the American Diabetes Association’s 85th Scientific Sessions.

Read more